UCare lost money on operations last year as the Minneapolis-based HMO saw a significant recovery in patient demand for health care services, including from people who likely deferred care during the pandemic period.
The red ink marked a departure from a three-year run of profits at UCare that included unusually high earnings in 2022 from Medicaid and related health insurance programs run by the state government.
The health plan took a 5% reduction in Medicaid rates last year and started to see enrollment declines in the program after the state resumed eligibility checks that had been suspended with the COVID-19 public health emergency.
“The higher medical cost ... is the result of increased utilization in pharmacy cost from prior year, and increased utilization of outpatient specialty services due to deferrals of preventive and elective care as well as provider contractual rate increases,” UCare said in a filing with regulators.
Since early last summer, health insurers and employers have been pointing to signs in the U.S. of rising medical costs, including more spending on medications.
In a statement to the Star Tribune, UCare singled out expenses for GLP-1s, a new group of drugs widely used for weight loss and diabetes, including well-known brands Ozempic and Wegovy. The state Medicaid program mandated coverage, UCare said, “but did not adjust payment rates to cover the explosive utilization increase of these new meds.”
The health plan also saw more costs for new RSV vaccines, UCare said, just as responsibility for covering the cost of COVID vaccines shifted from the federal government to health plans.
In 2023, UCare posted an operating loss of $82.1 million on $6.16 billion of revenue for a margin of -1.3%. It was a reversal from the previous year’s operating profit of $338.5 million on about $6 billion in revenue, meaning a margin of more than 5%.